SuppreMol follows two distinct strategies to develop novel treatment options for autoimmune and chronic inflammatory diseases as well as allergies. The development portfolio contains SM101, the soluble extracellular domain of Fcy Receptor IIB (FcyRIIB) and anti-FcyRIIB antibodies in IgG (SM201 and SM211) as well as IgE (SM301) format.

SuppreMol has been building a team of 18 experienced and highly skilled scientists and clinicians pioneering the development and understanding of the drug candidates and the important role in the treatment of autoimmune diseases. The management team has more than 50 years of combined operational experience in the pharmaceutical industry.

SuppreMol GmbH was founded in 2002 as a spin-off from the Max Planck Institute (MPI) of Biochemistry in Martinsried/Munich. The founders - Dr. Uwe Jacob, Dr. Peter Sondermann, and Prof. Dr. Robert Huber, Nobel Prize for Chemistry in 1988 - are internationally recognized experts in the field of protein crystallography. Using this technique they were able to identify the interaction of immunoglobulin G (IgG) antibodies with their cellular receptors termed Fcγ Receptors (FcyRs) at the atomic level. In 2005, SuppreMol was brought to corporate life with an initial seed investment.